Nuvation Bio Inc. Insider Trading

NUVB

Last 12 months

Insiders bought 118K and sold $9.18M on the open market.

38% of the selling was scheduled in advance under 10b5-1 plans. Chief Scientific Officer Gary Hattersley sold $2.67M on Nov 20, 2025, 100% of their stake, outside a plan.

Net open-market

−$9.06M

1 buy · 13 sales

Under a 10b5-1 plan

38%

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Jun 2026

Jun 9, 2026

Get an email when NUVB's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 19	Gary Hattersley Chief Scientific Officer	Sold10b5-1 plan	100,000	$7.09	709K	100%	Form 4
Jun 23	Philippe Sauvage Chief Financial Officer	Sold10b5-1 plan	47,668	$6.01	286K	79%	Form 4
Jun 23	Stacy Markel Chief People Officer	Sold10b5-1 plan	125,000	$6.03	754K	79%	Form 4
Jun 23	Kerry Wentworth Chief Regulatory Officer	Sold10b5-1 plan	63,000	$6.02	379K	54%	Form 4
Jun 9	Robert Mashal Director	Bought	25,000	$4.73	118K	13%	Form 4
Apr 17	Dongfang Liu Chief Medical Officer	Sold10b5-1 plan	50,000	$5.02	251K	74%	Form 4
Apr 17	Kerry Wentworth Chief Regulatory Officer	Sold10b5-1 plan	36,750	$5.01	184K	41%	Form 4
Apr 6	Kerry Wentworth Chief Regulatory Officer	Sold10b5-1 plan	200,000	$4.52	904K	79%	Form 4
Dec 1, 2025	Dongfang Liu Chief Medical Officer	SoldNo plan	150,000	$7.82	$1.17M	89%	Form 4
Nov 25, 2025 – Nov 26, 2025	Dongfang Liu Chief Medical Officer	SoldNo plan 2 parts	20,000	$7.75 average	155K	53%	Form 4
Nov 20, 2025	Dongfang Liu Chief Medical Officer	SoldNo plan	20,000	$7.00	140K	53%	Form 4
Nov 20, 2025	Gary Hattersley Chief Scientific Officer	SoldNo plan 2 parts	369,051	$7.23 average	$2.67M	100%	Form 4
Nov 19, 2025	David C. Hanley Chief Technical Operations	SoldNo plan	200,000	$7.14	$1.43M	89%	Form 4
Nov 17, 2025 – Nov 19, 2025	Dongfang Liu Chief Medical Officer	SoldNo plan 2 parts	30,000	$4.94 average	148K	63%	Form 4
Oct 27, 2025	Gary Hattersley Chief Scientific Officer	Sold10b5-1 plan	100,000	$5.02	502K	100%	Form 4
Jun 18, 2025	Stacy Markel Chief People Officer	Bought	10,000	$1.71	17K	51%	Form 4
Jun 16, 2025 – Jun 17, 2025	Philippe Sauvage Chief Financial Officer	Bought 2 parts	7,300	$1.81 average	13K	281%	Form 4
Jun 16, 2025	Colleen Sjogren Chief Commercial Officer	Bought	50,000	$1.81	91K	161%	Form 4
Jun 16, 2025	Kerry Wentworth Chief Regulatory Officer	Bought 2 parts	50,000	$1.79 average	90K	New	Form 4
Jun 16, 2025	David Hung President and CEO	Bought	500,000	$1.79	895K	0.9%	Form 4
May 2, 2025	Dongfang Liu Chief Medical Officer	Sold10b5-1 plan	20,000	$2.50	50K	63%	Form 4
Apr 4, 2025 – Apr 7, 2025	David Hung President and CEO	Bought 2 parts	500,000	$1.64 average	821K	0.9%	Form 4
Apr 1, 2025	Robert Mashal Director	Bought 2 parts	100,000	$1.67 average	167K	100%	Form 4
Nov 11, 2024	Junyuan Jerry Wang CEO, Anheart Therapeutics Ltd.	SoldNo plan	56,361	$2.89	163K	0.9%	Form 4

Aug 1910b5-1 plan
Gary Hattersley
Chief Scientific Officer · sold 100,000 at $7.09
709K
100% of stake
Jun 2310b5-1 plan
Philippe Sauvage
Chief Financial Officer · sold 47,668 at $6.01
286K
79% of stake
Jun 2310b5-1 plan
Stacy Markel
Chief People Officer · sold 125,000 at $6.03
754K
79% of stake
Jun 2310b5-1 plan
Kerry Wentworth
Chief Regulatory Officer · sold 63,000 at $6.02
379K
54% of stake
Jun 9
Robert Mashal
Director · bought 25,000 at $4.73
118K
13% of stake
Apr 1710b5-1 plan
Dongfang Liu
Chief Medical Officer · sold 50,000 at $5.02
251K
74% of stake
Apr 1710b5-1 plan
Kerry Wentworth
Chief Regulatory Officer · sold 36,750 at $5.01
184K
41% of stake
Apr 610b5-1 plan
Kerry Wentworth
Chief Regulatory Officer · sold 200,000 at $4.52
904K
79% of stake
Dec 1, 2025No plan
Dongfang Liu
Chief Medical Officer · sold 150,000 at $7.82
$1.17M
89% of stake
Nov 25, 2025 – Nov 26, 2025No plan
Dongfang Liu
Chief Medical Officer · sold 20,000 at avg $7.75
155K
53% of stake
Nov 20, 2025No plan
Dongfang Liu
Chief Medical Officer · sold 20,000 at $7.00
140K
53% of stake
Nov 20, 2025No plan
Gary Hattersley
Chief Scientific Officer · sold 369,051 at avg $7.23
$2.67M
100% of stake
Nov 19, 2025No plan
David C. Hanley
Chief Technical Operations · sold 200,000 at $7.14
$1.43M
89% of stake
Nov 17, 2025 – Nov 19, 2025No plan
Dongfang Liu
Chief Medical Officer · sold 30,000 at avg $4.94
148K
63% of stake
Oct 27, 202510b5-1 plan
Gary Hattersley
Chief Scientific Officer · sold 100,000 at $5.02
502K
100% of stake
Jun 18, 2025
Stacy Markel
Chief People Officer · bought 10,000 at $1.71
17K
51% of stake
Jun 16, 2025 – Jun 17, 2025
Philippe Sauvage
Chief Financial Officer · bought 7,300 at avg $1.81
13K
281% of stake
Jun 16, 2025
Colleen Sjogren
Chief Commercial Officer · bought 50,000 at $1.81
91K
161% of stake
Jun 16, 2025
Kerry Wentworth
Chief Regulatory Officer · bought 50,000 at avg $1.79
90K
New position
Jun 16, 2025
David Hung
President and CEO · bought 500,000 at $1.79
895K
0.9% of stake
May 2, 202510b5-1 plan
Dongfang Liu
Chief Medical Officer · sold 20,000 at $2.50
50K
63% of stake
Apr 4, 2025 – Apr 7, 2025
David Hung
President and CEO · bought 500,000 at avg $1.64
821K
0.9% of stake
Apr 1, 2025
Robert Mashal
Director · bought 100,000 at avg $1.67
167K
100% of stake
Nov 11, 2024No plan
Junyuan Jerry Wang
CEO, Anheart Therapeutics Ltd. · sold 56,361 at $2.89
163K
0.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NUVB, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NUVB

CompareIntrinsic value

DAWNDay One Biopharmaceuticals, Inc.

No recent price10

ABUSArbutus Biopharma Corporation

$4.06+4.64%60

LFVNLifeVantage Corporation

$5.97+3.65%73

MGNXMacrogenics Inc.

$2.31-0.86%36

AMRNAmarin Corp PLC\Uk

$12.25+1.66%46

CYRXCryoport Inc.

$16.70+1.52%13

HRTXHeron Therapeutics Inc.

$0.30+7.14%36

KPTIKaryopharm Therapeutics Inc.

$0.07-17.16%15

Held by ETFs

NUVB is in 37 US ETFs. The largest of them, with NUVB's weight in each:

Spot a number that looks wrong? Check it in NUVB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NUVB

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.